Savior Lifetec Corporation announced that it is signed a sales contract with Shenzhen China Resources GOSUN Pharmaceuticals, authorizing the company to exclusively sell the company's ertapenem injection products in the mainland market. Effect on company finances and business: Accelerating the introduction of ertapenem into the Chinese mainland market will help increase the global market share of the company's products. Concrete purpose/objective: Through this cooperation project, the company will open a new milestone in the company's mainland market sales.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23 TWD | +0.66% | +7.73% | +2.45% |
1st Jan change | Capi. | |
---|---|---|
+2.45% | 226M | |
+21.28% | 44.4B | |
+24.60% | 23.03B | |
+18.59% | 15.14B | |
+12.87% | 13.12B | |
+44.67% | 11.85B | |
-8.33% | 6.99B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+12.22% | 5.52B |
- Stock Market
- Equities
- 4167 Stock
- News Savior Lifetec Corporation
- Savior Lifetec Corporation and Shenzhen China Resources Gosun Pharmaceutical Co.,Ltd Signs Exclusive Sales Contract for Ertapenem in the Mainland Market